Study groups were stratified both clinically and neuropathologically using standard diagnostic neuropathologic criteria from the National Institute on Aging and Alzheimer’s Association (NIA-AA) for assessment of AD neuropathologic change (i.e., amyloid-β and Tau tangles), Lewy body disease, hippocampal sclerosis of aging, and vascular lesions.19 Neuropathological assessments for frontotemporal lobar degeneration with Tau pathology (FTLD-Tau) (i.e. progressive supranuclear palsy and corticobasal degeneration) was performed using standard diagnostic criteria. The gene discussed is MAPT; the disease is Alzheimer disease.